Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

Benzinga Newsdesk www.benzinga.com Neutral 50.6%

Neg 0% Neu 50.6% Pos 0%

Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.